更新于：2024-11-01

Vejle Hospital

Denmark

更新于：2024-11-01

概览

概览

关联

170

项与 Vejle Hospital 相关的临床试验

NCT06647472 / Not yet recruitingN/AIIT

Proteomic Analysis on Myopic Children Using Orthokeratology Lenses With Good or Poor Myopic Control. The ProMOC Study

The key objective of the study is to gain an understanding of the biochemical processes that contribute to orthokeratology lenses being more effective in specific individuals compared to others. With this knowledge, we hope to optimize treatment effectiveness in those currently experiencing less favorable outcomes from treatment in the future.
The primary aim is to investigate differences in protein levels in children using orthokeratology lenses with various effects of myopia control.
Hypothesis: There is a significant difference in the expression of molecules in children with various effects of myopia control.

开始日期2024-10-21

申办/合作机构

Vejle Hospital

[+1]

NCT05776381 / Not yet recruiting临床2期IIT

The Impact of an In-consultation Patient Decision Aid on Treatment Choices and Outcomes of Management for Patients With an Unexpected Malignant Colorectal Polyp A Non-randomized Clinical Phase II Study

Management of unexpected malignant colorectal polyps removed endoscopically can be challenging due to the risk of residual tumor and lymphatic spread. International studies have shown that in patients choosing surgical management instead of watchful waiting, 54-82% of bowel resections are without evidence of residual tumor or lymphatic spread. As surgical management entails risks of complications and watchful waiting management entails risks of residual disease or recurrence, a clinical dilemma arises when choosing a management strategy.
Shared decision making (SDM) is a concept that can be used in preference sensitive decision making to facilitate patient involvement, empowerment, and active participation in the decision making process.
This is a clinical multicenter, non-randomized, interventional phase II study involving Danish surgical departments planned to commence in the first quarter of 2024. The aim of the study is to examine whether shared decision making and using a patient decision aid (PtDA) in consultations affects patients' choice of management compared with historical data. The secondary aim is to investigate Patient Reported Experience Measures (PREMs) and Patient Reported Outcome Measures (PROMs) using questionnaire feedback directly from the patients.

开始日期2024-09-01

申办/合作机构

Vejle Hospital

NCT06562348 / Not yet recruiting临床2期IIT

ctDNA Guided Palliative Systemic Therapy Compared to Standard Care in Metastatic Cancer - The Randomized ctDNA-RECIST Trial

A study investigating if analysis of circulating tumor DNA (ctDNA) can guide palliative treatment in patients with gastrointestinal cancer.

开始日期2024-09-01

申办/合作机构

Århus Universitetshospital

[+1]

100 项与 Vejle Hospital 相关的临床结果

登录后查看更多信息

0 项与 Vejle Hospital 相关的专利（医药）

登录后查看更多信息

1,014

项与 Vejle Hospital 相关的文献（医药）

2024-11-01·The American Journal of Surgery

Body image and psychosocial effects in women after treatment of breast cancer: A prospective study

Article

作者: Grosen, Kasper ; Ventzel, Lise ; Bennedsgaard, Kristine Tang ; Finnerup, Nanna Brix ; Andersen, Inge Scheel ; Jensen, Ditte Mee Ran

PURPOSETo explore treatment-related, socio-economic, and psychological factors influencing body image and return to work.MATERIALS AND METHODS137 patients participated in the study. A questionnaire was completed before surgery and at 1-year follow-up, where patients were also interviewed in person with questions modified from the Body Image Scale and the sexual adjustment scale as well as questions about their work status.RESULTSThere was a significant decline in body image score from baseline to 1-year follow-up related to younger age, more extensive surgery and post-surgery treatments. Treatment with adjuvant chemotherapy was associated with a lower rating on ability to work in relation to mental requirements and later return to work. Higher anxiety scores at baseline were associated with both a decline in body image and a delay in return to work.CONCLUSIONBreast cancer surgery can affect body image and especially adjuvant chemotherapy seems to affect work ability. However, personal characteristics are also involved and thus should be considered when planning for treatment of breast cancer.

2024-10-01·Radiotherapy and Oncology

Evaluating Danish Breast Cancer Group locoregional radiotherapy guideline adherence in clinical treatment data 2008–2016: The DBCG RT Nation study

Article

作者: Maae, Else ; Nørring Bekke, Susanne ; Sofia Korreman, Stine ; Refsgaard, Lasse ; Jensen, Ingelise ; Bech Jellesmark Thorsen, Lise ; Louise Holm Milo, Marie ; Skarsø Buhl, Emma ; Holck Nielsen, Mette ; Boye, Kristian ; Berg, Martin ; Vestmø Maraldo, Maja ; Vrou Offersen, Birgitte ; Saini, Abhilasha ; Laugaard Lorenzen, Ebbe ; Al-Rawi, Sami ; Yates, Esben ; Wichmann Matthiessen, Louise

BACKGROUND AND PURPOSEGuideline adherence in radiotherapy is crucial for maintaining treatment quality and consistency, particularly in non-trial patient settings where most treatments occur. The study aimed to assess the impact of guideline changes on treatment planning practices and compare manual registry data accuracy with treatment planning data.MATERIALS AND METHODSThis study utilised the DBCG RT Nation cohort, a collection of breast cancer radiotherapy data in Denmark, to evaluate adherence to guidelines from 2008 to 2016. The cohort included 7448 high-risk breast cancer patients. National guideline changes included, fractionation, introduction of respiratory gating, irradiation of the internal mammary lymph nodes, use of the simultaneous integrated boost technique and inclusion of the Left Anterior Descending coronary artery in delineation practice. Methods for structure name mapping, laterality detection, detection of temporal changes in population mean lung volume, and dose evaluation were presented and applied. Manually registered treatment characteristic data was obtained from the Danish Breast Cancer Database for comparison.RESULTSThe study found immediate and consistent adherence to guideline changes across Danish radiotherapy centres. Treatment practices before guideline implementation were documented and showed a variation among centres. Discrepancies between manual registry data and actual treatment planning data were as high as 10% for some measures.CONCLUSIONNational guideline changes could be detected in the routine treatment data, with a high degree of compliance and short implementation time. Data extracted from treatment planning data files provides a more accurate and detailed characterisation of treatments and guideline adherence than medical register data.

2024-10-01·Radiotherapy and Oncology

Feasibility of weekly cisplatin and radiotherapy for localized anal cancer – A Danish anal cancer group report

Article

作者: Garm Spindler, Karen-Lise ; Lycke Wind, Karen ; Jensenius Skovhus Kronborg, Camilla ; Mayland Havelund, Birgitte ; Vittrup Jakobsen, Anne ; Kjer Oksen, Rikke

BACKGROUNDChemoradiotherapy (CRT) with flourouracil and mitomycin is the standard treatment for squamous cell carcinomas of the anus (SCCA), however the associated acute toxicity often hinders compliance. Although weekly cisplatin is a well-established treatment for other squamous cell carcinomas, it has not been explored in SCCA.PURPOSETo investigate if radiotherapy (RT) with weekly cisplatin is a feasible option for SCCA and to report the acute toxicity.MATERIAL/METHODSPatients were treated with RT and weekly cisplatin 40 mg/m2 between 1998-2020. Retrospective data from medical records (n=65) and prospectively collected data from an observational study (n=51) comprising physician assessed toxicity (NCI-CTCAE 4.0), patient-reported outcomes (EORTC-QlQC30 + CR29) baseline, mid-therapy, end of treatment and 2-4 weeks post-treatment were included. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method.RESULTSWe included 116 patients. T-stages were T1:4%, T2: 71%, T3: 17%, T4: 8% and 47% has N+ disease. RT doses were 53.75-64 Gy/45-51.2 Gy and the mean cumulative dose of cisplatin was 307.5 mg. The median overall treatment time was 43 days. Within 6 months after CRT 88.9 % had complete response. The median follow-up time was 4.5 years and 5-year DFS and OS were 77% (95%CI 68.7;84.5%) and 86.4% (95%CI 78.3;91.7%), respectively. Hospitalization occured in 20% with 2.6% being admitted due to febrile neutropenia. Hematological toxicity was low with 13.7% grade 3 and 3.9% grade 4. Anal pain, skin, gastrointestinal and urogenital toxicity were mild.CONCLUSIONRT and weekly cisplatin for SCCA showed good outcome results and an acceptable acute toxicity profile.

项与 Vejle Hospital 相关的新闻（医药）

2024-02-23

·PRNewswire

RaySearch Laboratories: Year-end report 2023

STOCKHOLM, Feb. 23, 2024 /PRNewswire/ -- FOURTH QUARTER (OCTOBER - DECEMBER 2023) Order intake SEK 317.7 M (514.4) Net sales SEK 299.6 M (264.4) Operating profit SEK 44.4 M (20.7) Profit after tax SEK 31.5 M (14.1) Earnings per share before/after dilution SEK 0.92 (0.41) Cash flow SEK 45.5 M (42.8) Order backlog SEK 1,864.4 M (1,940.1) at the end of the period TWELVE MONTHS (JANUARY - DECEMBER 2023) Order intake SEK 1,004.2 M (1,218.5) Net sales SEK 1,022.2 M (843.6) Operating profit SEK 114.9 M (42.7) Profit after tax SEK 81.6 M (23.8) Earnings per share before/after dilution SEK 2.38 (0.69) Cash flow SEK 190.3 M (46.8) The Board of Directors proposes an ordinary dividend of SEK 0.70 (0) per share which corresponds to 30 percent of the group profit for the period in accordance with the dividend policy. Additionally, the Board of Directors proposes an extra dividend of SEK 1.30 (0) per share. SIGNIFICANT EVENTS DURING THE FOURTH QUARTER RaySearch secured an order from Israel-based P-Cure and expanded collaboration focusing on advanced proton therapy solutions. Paul Scherrer Institute in Switzerland placed an order for RayStation. The Mass General Cancer Center in the US placed an order and thereby expanded its installation of RayStation to also include proton treatment planning. Vejle Hospital in Denmark became the first center in the world to use RayStation for an online adaptive treatment with augmented CBCT. The hospital chain Froedtert & Medical College of Wisconsin, US, placed an order for RayStation. SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD The number of radiation therapy centers that have chosen RayStation for treatment planning now exceeds 1,000. The Royal Marsden in the UK will be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch. RaySearch acquired the product DrugLog from Pharmacolog. FOR FURTHER INFORMATION, PLEASE CONTACT: Johan Löf, CEO Telephone: +46 (0)8 510 530 00, [email protected] Annika Blondeau Henriksson, Interim CFO Telephone: +46 (0)8 510 530 00, [email protected] The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 23, 2024 at 7:45 a.m. CET. WEBCAST CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch's year-end report for January-December 2023 at a webcast to be held in English on Friday, February 23, 2024 at 10:00-10:30 a.m. CET. Link to webcast: RaySearch Q4, 2023 You can also join the webcast by phone: Sverige: +46 (0) 8 505 100 31 UK: +44 (0) 207 107 06 13 US: +1 (1) 631 570 56 13 The following files are available for download: SOURCE RaySearch Laboratories

放射疗法

2023-11-20

·PRNewswire

Vejle Hospital becomes first center in the world to use RayStation for an online adaptive treatment with augmented CBCT

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that University Hospital of Southern Denmark in Vejle, Denmark has developed a new and groundbreaking workflow for adapting a patient's treatment plan during the first treatment session. The improved workflow is enabled by the adaptive replanning capabilities of RayStation®* and significantly saves time for the patient. The first patient was successfully treated on October 10. In this workflow a preliminary treatment plan is prepared on the already available diagnostic CT scan rather than acquiring an additional CT scan for the purpose of treatment planning, which is the standard method today. This marks a significant benefit to the patient that no longer needs to wait for the additional CT appointment. The plan prepared on the diagnostic CT scan cannot be used without modifications due to different patient positioning at image acquisition compared to treatment delivery. Thanks to the synthetic CT algorithm and fast adaptive replanning capabilities in RayStation, the CBCT of the first treatment fraction can be used for creating an adapted plan during the treatment session. In this workflow, the CBCT is augmented with use of the diagnostic CT, and a new plan is created, which is used in the first and any subsequent fractions. The first patient - a 65-year-old man diagnosed with metastatic prostate cancer - was successfully treated on October 10. The patient was prescribed a 30 Gy regimen over 10 fractions. His treatment employed a VMAT (volumetric modulated arc therapy) arc on an Elekta C-arm linac. In the current example, the online adaptation was motivated by differences in positioning at image acquisition and at treatment. The powerful tools in RayStation have the potential of also addressing other anatomical changes. Rune S. Thing, medical physicist at Vejle Hospital, says: "We are dedicated to pushing the boundaries of innovation for improved patient care and operational excellence. Our goal with the new workflow is to significantly reduce the time that a patient undergoing short-course palliative radiotherapy has to stay in the hospital." Johan Löf, founder and CEO, RaySearch, says: "Online adaptive has been a key focus for RaySearch for many years and I am impressed by the work that is done at Vejle. RayStation has very advanced tools available for taking online adaptive into clinical routine and the work done by Vejle is showcasing what groundbreakning possibilities our users have to further advance cancer treatments." For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00 [email protected] The following files are available for download: SOURCE RaySearch Laboratories

100 项与 Vejle Hospital 相关的药物交易

登录后查看更多信息

100 项与 Vejle Hospital 相关的转化医学

登录后查看更多信息